Effect of long-acting erythropoiesis-stimulating agents on hemoglobin levels at the initiation of dialysis

Table 4 Independent association of use and dose of long-acting ESA with Hb level by multiple linear regression analysis

Model	Adjustment		Regression coefficient	95 % CI		P
Model 1^a	Unadjusted	Long-acting ESA	0.204	0.515	1.02	.000
Model 1^a	Unadjusted	Dose of ESA/1000 units	0.024	−0.007	0.014	.483
Model 2^b	Age, sex, diabetes, BMI, SBP, vascular access, nephrologists care, CTR	Long-acting ESA	0.191	0.427	0.976	.000
Model 2^b		Dose of ESA/1000 units	−0.019	−0.014	0.008	.613
Model 3^c	Model 2 + albumin, CRP	Long-acting ESA	0.169	0.341	0.912	.000
Model 3^c	Model 2 + albumin, CRP	Dose of ESA/1000 units	−0.013	−0.013	0.009	.721
Model 4^d	Model 2 + TC, TG,HDL-C, Glu	Long-acting ESA	0.196	0.41	1.039	.000
Model 4^d	Model 2 + TC, TG,HDL-C, Glu	Dose of ESA/1000 units	−0.023	−0.017	0.01	.588
Model 5^e	Model 2 + Ca, P, iPTH, vitamin D	long-acting ESA	0.186	0.388	0.948	.000
Model 5^e	Model 2 + Ca, P, iPTH, vitamin D	Dose of ESA/1000 units	−0.022	−0.015	0.008	.570
Model 6^f	Model 2 + Fe, TIBC, ferritin, iron tx	Long-acting ESA	0.168	0.275	0.848	.000
Model 6^f	Model 2 + Fe, TIBC, ferritin, iron tx	Dose of ESA/1000 units	−0.029	−0.018	0.009	.503
Model 7^g	Model 2 + ACEI/ARB, AST-120	Long-acting ESA	0.188	0.411	0.962	.000
Model 7^g	Model 2 + ACEI/ARB, AST-120	Dose of ESA/1000 units	−0.016	−0.014	0.009	.683
Model 8^h	All	Long-acting ESA	0.155	0.176	0.858	.003
Model 8^h	All	Dose of ESA/1000 units	−0.029	−0.019	0.01	.555

^aUnadjusted
^bAdjusted for age, sex, diabetes nephropathy, BMI, SBP, vascular access, duration of nephrologists care, and CTR
^cAdjusted for variables in model 2 plus albumin and CRP
^dAdjusted for variables in model 2 plus total cholesterol, triglyceride, high lipoprotein cholesterol, and glucose
^eAdjusted for variables in model 2 plus calcium, phosphate, and intact-PTH
^fAdjusted for variables in model 2 plus Fe, TIBC, ferritin, and usage of iron medication
^gAdjusted for variables in model 2 plus usage of angiotensin-converting enzyme inhibitors, angiotensin-II receptor blockers, and AST-120
^hAdjusted for all variables from model 2 to 7

ISSN: 2059-1381